Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Beraksurf versus Survanta and Curosurf in preterm neonates with respiratory distress syndrome
IRCT20201213049705N1Phase 3Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- Oct 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of beractant and Poractant alfa in respiratory distress syndrome (RDS) (3 arms), sponsored by Tehran University of Medical Sciences. Primary endpoints: Oxygen index and Duration of ventilation. Started Oct 2019; status: completed.
02
Drugs
beractantPoractant alfa
03
Conditions
respiratory distress syndrome (RDS)
Beyond the preview
Go deeper on IRCT20201213049705N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20201213049705N1.